The present invention provides a liquid aqueous formulation for the intranasal administration of apomorphine, which comprises:(a) at least about 15 mg/ml of apomorphine； and(b) a solubilising agent selected from(i) at least one polyoxyethylene-polyoxypropylene copolymer(poloxamer)；(ii) at least one cyclodextrin； and(iii) at least one cyclodextrin together with chitosan. The formulations of the invention can be used in the treatment/management of Parkinson's disease.本發明提供用於鼻內投予阿朴嗎啡之液體水性調配物，其包含：(a)至少約15mg/mL之阿朴嗎啡；及(b)選自以下者之增溶劑：(i)至少一種聚氧乙烯-聚氧丙烯共聚物(泊洛沙姆)；(ii)至少一種環糊精；及(iii)至少一種環糊精及殼聚糖。本發明之調配物可用於治療/控制帕金森氏病。
